VRTX - VERTEX PHARMACEUTICALS INC / MA
IEX Last Trade
411.11
-0.475 -0.116%
Share volume: 83,733
Last Updated: Wed 08 Jan 2025 08:30:16 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.55%
PREVIOUS CLOSE
CHG
CHG%
$411.58
-0.47
-0.12%
Fundamental analysis
46%
Profitability
67%
Dept financing
7%
Liquidity
62%
Performance
30%
Performance
5 Days
0.30%
1 Month
-13.85%
3 Months
-11.03%
6 Months
-15.27%
1 Year
-2.58%
2 Year
44.17%
Key data
Stock price
$411.11
DAY RANGE
$402.14 - $411.95
52 WEEK RANGE
$396.14 - $519.88
52 WEEK CHANGE
-$5.86
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Reshma Kewalramani
Region: US
Website: vrtx.com
Employees: 4,800
IPO year: 1991
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: vrtx.com
Employees: 4,800
IPO year: 1991
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial.
Recent news